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Common variation in COL4A1/COL4A2
is associated with sporadic cerebral small
vessel disease
ABSTRACT
Objectives: We hypothesized that common variants in the collagen genes COL4A1/COL4A2 are
associated with sporadic forms of cerebral small vessel disease.
Methods: We conducted meta-analyses of existing genotype data among individuals of European
ancestry to determine associations of 1,070 common single nucleotide polymorphisms (SNPs) in
the COL4A1/COL4A2 genomic region with the following: intracerebral hemorrhage and its sub-
types (deep, lobar) (1,545 cases, 1,485 controls); ischemic stroke and its subtypes (cardioem-
bolic, large vessel disease, lacunar) (12,389 cases, 62,004 controls); and white matter
hyperintensities (2,733 individuals with ischemic stroke and 9,361 from population-based co-
horts with brain MRI data). We calculated a statistical significance threshold that accounted for
multiple testing and linkage disequilibrium between SNPs (p , 0.000084).
Results: Three intronic SNPs in COL4A2 were significantly associated with deep intracerebral
hemorrhage (lead SNP odds ratio [OR] 1.29, 95% confidence interval [CI] 1.14–1.46, p 5
0.00003; r2 . 0.9 between SNPs). Although SNPs associated with deep intracerebral hemor-
rhage did not reach our significance threshold for association with lacunar ischemic stroke (lead
SNP OR 1.10, 95% CI 1.03–1.18, p 5 0.0073), and with white matter hyperintensity volume in
symptomatic ischemic stroke patients (lead SNP OR 1.07, 95% CI 1.01–1.13, p 5 0.016), the
direction of association was the same. There was no convincing evidence of association with
white matter hyperintensities in population-based studies or with non–small vessel disease cer-
ebrovascular phenotypes.
Conclusions: Our results indicate an association between common variation in the COL4A2 gene
and symptomatic small vessel disease, particularly deep intracerebral hemorrhage. These find-
ings merit replication studies, including in ethnic groups of non-European ancestry. Neurology®
2015;84:918–926
GLOSSARY
CE 5 cardioembolic; CHARGE 5 Cohorts for Heart and Aging Research in Genomic Epidemiology; CI 5 confidence interval;
eQTL 5 expression quantitative trait locus; GTEx 5 Genotype-Tissue Expression; ICH 5 intracerebral hemorrhage; ISGC 5
International Stroke Genetics Consortium; LD 5 linkage disequilibrium; LVD 5 large vessel disease; OR 5 odds ratio;
SNAP 5 SNP Annotation and Proxy Search; SNP 5 single nucleotide polymorphism; SVD 5 small vessel disease; WMH 5
white matter hyperintensity.
Small vessel diseases of the brain include a distinct subtype (hereafter referred to in this report as
“cerebral SVD”) that affects the small, deep, penetrating arteries and arterioles of the brain, and is
thought to be responsible for most symptomatic lacunar ischemic strokes and deep intracerebral
hemorrhages (ICHs), as well as for “clinically silent” brain MRI features, such as white matter
hyperintensities (WMH). This cerebral SVD also contributes to cognitive impairment and demen-
tia in older people, both through clinically symptomatic strokes and clinically silent ischemia.1
Despite increasing evidence supporting a distinct vascular pathology for cerebral SVD compared
with other subtypes of cerebrovascular disease, our knowledge of the underlying genes and patho-
physiologic mechanisms is limited, with a lack of specific treatment strategies.1 Common polymor-
phisms studied in genome-wide association studies (GWAS) of ICH, ischemic stroke, andWMH to
date appear to contribute little to the risk of cerebral SVD, despite its established heritability.2–4
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COL4A1 and COL4A2 genes are located in
tandem on chromosome 13q34 and have a
shared communal bidirectional promoter.
They encode the collagen chains a1(IV) and
a2(IV), which constitute a major component
of the vascular basement membrane.5 Domi-
nant missense mutations in COL4A1/COL4A2
cause rare familial forms of cerebral SVD, man-
ifesting as deep ICHs, lacunar ischemic strokes,
and WMH.6,7 Genes causing rare familial
forms of cerebral SVD may also contain var-
iants conferring risk for common forms of cere-
bral SVD.8–10 We therefore hypothesized that
variants in the COL4A1 and COL4A2 genes
may confer risk for common cerebral SVD.
METHODS Identification of participating studies.
Through an established network of collaborations with relevant
groups and consortia (International Stroke Genetics Consortium
[ISGC, http://www.strokegenetics.org/], the METASTROKE
Collaboration,2 the WMH in Ischemic Stroke GWAS
Collaboration,11 and the CHARGE [Cohorts for Heart and
Aging Research in Genomic Epidemiology] WMH Group3
[http://web.chargeconsortium.com/]), we identified and included
data from the majority of currently available large GWAS of
relevant cerebrovascular phenotypes in individuals of European
ancestry. The entire dataset consisted of the following: 3 cohorts
of 1,545 patients with ICH and 1,485 controls, including
information on the main ICH subtypes (deep and lobar); 15
cohorts of 12,389 patients with ischemic stroke, including
information on the main determined TOAST (Trial of Org
10172 in Acute Stroke Treatment) subtypes (large vessel disease
[LVD], cardioembolic [CE], and small vessel disease/lacunar
ischemic stroke)12 and 62,004 controls; 9 cohorts of 2,733
ischemic stroke patients; and 7 cohorts of 9,361 individuals from
population-based studies with brain MRI-based measures of
WMH volume (table 1). Table e-1 on the Neurology® Web site
at Neurology.org includes detailed descriptions of the design and
characteristics of the participating studies.2–4,11,13–15
Data collection from participating studies. We collected ex-
isting genotype data from participating studies for the COL4A1
and COL4A2 genomic region of approximately 464 kilo base
pairs (kbp), which includes .1,000 single nucleotide polymor-
phisms (SNPs) covering the bidirectional communal promoter,
introns, exons, and a 50-kbp upstream and downstream flanking
region (Human Genome reference build 19 [hg19] coordinates
110.751.310–111.215.373). For each phenotype (deep ICH,
lobar ICH, all ICH, lacunar ischemic stroke, CE ischemic
stroke, LVD ischemic stroke, all ischemic stroke, WMH
volume in ischemic stroke and in population-based studies), we
collected the following cohort-level summary genotype-
phenotype association data for all directly genotyped and
imputed SNPs in the region: SNP reference (rs) number and
position; effect allele/noneffect allele and their frequencies;
association effect size estimate (b coefficient); standard error of
the b coefficient; p value for the association; and, for imputed
SNPs, the imputation quality measure used and its value. In
addition, we collected data on study design and characteristics
from relevant publications, as well as by direct communication
with group/consortium leads, individual study principal
investigators, and other study team members.
Data analysis. Meta-analyses of COL4A1/COL4A2 SNPs for
each phenotype. We performed meta-analyses of the genotype
summary data, from each contributing cohort, assessing associa-
tions of COL4A1 and COL4A2 SNPs with each of the cerebro-
vascular phenotypes available, both those assumed to represent
cerebral SVD specifically (deep ICH, lacunar ischemic stroke,
WMH volume in ischemic stroke and in population-based studies)
and others (lobar ICH, all ICH, CE ischemic stroke, LVD ischemic
stroke, all ischemic stroke). We hypothesized that associations
would be specific to, or at least strongest with, cerebral SVD
phenotypes. We used a fixed-effects inverse variance–based model
in METAL genetic meta-analysis software, which weights the b
coefficients by their estimated standard errors.16 We used a case-
control approach for ICH, ischemic stroke, and their subtypes,
generating for each SNP odds ratios (ORs) per additional minor
allele for being a case vs control. We used a quantitative trait
approach for WMH analysis, assessing for each SNP the effect per
additional minor allele on the natural log-transformed WMH
volume. Details of WMH volume measurements are provided in
table e-1.
Quality-control measures had been applied to all individual
studies before provision of data (table e-1). Data from the
included studies had been imputed to different reference datasets
(HapMap II, HapMap III, or 1000 Genomes) using a range of
imputation software (IMPUTE, MACH, and BimBam)17 and
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Table 1 Participating studies
Phenotype Collections
Sample size
Cases Controls
ICH 3 cohorts from the ISGC ICH GWAS consortium 1,545 all ICH: 874 deep,a 671 lobar 1,485
IS 15 cohorts from the ISGC/METASTROKE
Consortium of IS case-control studies
12,389 all IS: 2,405 CE, 2,167 LVD,
1,854 lacunara
62,004
WMH in IS 9 IS cohorts including individuals with brain MRI
data on WMH
2,733 individualsa
WMH in population 7 population-based cohorts in the CHARGE
Consortium including individuals with brain MRI
data on WMH
9,361 individualsa
Abbreviations: CE 5 cardioembolic; CHARGE 5 Cohorts for Heart and Aging Research in Genomic Epidemiology; GWAS 5
genome-wide association studies; ICH 5 intracerebral hemorrhage; IS 5 ischemic stroke; ISGC 5 International Stroke
Genetics Consortium; LVD 5 large vessel disease; WMH 5 white matter hyperintensity.
a Indicates small vessel disease phenotypes.
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were provided with reference to 1 of 2 different Human Genome
reference builds (hg18 or hg19) (table e-1).18–20 To permit con-
sistent analyses and interpretation of the data across all included
phenotypes and studies, we converted all the data to the same
reference build (hg19) and limited the analyses to SNPs present in
the HapMap II CEU population (Utah residents of northern and
western European ancestry) only. This strategy provided us with
the maximum set of 1,070 SNPs represented in all studies and
phenotypes. We filtered these data based on imputation quality
scores (r2 $ 0.3 [MACH, BimBam, IMPUTE]; info score $0.7
[PLINK]) and minor allele frequency $1%.
Calculating the significance threshold. To allow for multi-
ple testing, we used a modified version of the Nyholt method
(MeffLi), which takes into account the linkage disequilibrium
(LD) between SNPs: based on the spectral decomposition of
matrices of pairwise LD between SNPs, it calculates the “effective
number” (N) of SNPs tested, using this number to calculate the
statistical significance threshold by applying the Bonferroni cor-
rection for N independent tests (p , 0.05/N). We used the
publicly available HapMap II CEU dataset genotype information
to calculate N using the Web interface http://gump.qimr.edu.au/
general/daleN/SNPSpD/. The Nyholt method is more appro-
priate for these data than the standard Bonferroni correction,
which would be overly conservative because of the assumption
that all SNPs are independent.21,22 This method controls accu-
rately for the error rate in evaluations of real and simulated
data.23,24
Further exploration of significant SNPs across all
phenotypes. For any SNPs significantly associated with any of
the 9 phenotypes assessed, we examined associations with all
other phenotypes, focusing on comparisons of findings for
cerebral SVD phenotypes (deep ICH, lacunar ischemic stroke,
WMH) vs non-SVD phenotypes. We displayed ORs together
with their 95% confidence intervals (CIs) and p values using
forest plots, to indicate the size and direction of associations across
phenotypes. To display the data across all phenotypes in a uni-
form way, we performed data manipulations to express the SNP
effect on WMH volume as OR per 1-unit SD change in WMH
volume (table e-2).
We assessed the consistency of results for significantly associ-
ated SNPs through conducting formal I2 and x2 tests for statistical
heterogeneity of results between individual cohorts.25
Functional annotation of SNPs. For SNPs with significant
associations, we extracted a list of all other SNPs in moderate LD
(defined as r2 $ 0.3) from the Web-based SNP Annotation and
Proxy Search (SNAP) tool (http://www.broadinstitute.org/mpg/
snap/), based on CEU population data from the 1000 Genomes
pilot 1.26 We then obtained the functional annotation data for
these SNPs from the Ensembl genome browser (http://www.
ensembl.org/index.html), Seattle Seq (http://snp.gs.washington.
edu/SeattleSeqAnnotation138/), and Haploreg v2 (http://www.
broadinstitute.org/mammals/haploreg/haploreg.php) databases,27–29
using all 3 databases with partly overlapping sources of infor-
mation to ensure consistency of results. We further explored the
functional significance of SNPs that were in high LD (r2 $ 0.9)
with the significant SNPs from our analyses, using the online
Genotype-Tissue Expression (GTEx) Portal eQTL (expression
quantitative trait locus) browser (http://www.broadinstitute.org/
gtex/) and the RegulomeDB database (http://regulome.stanford.
edu/).30,31 An eQTL represents a locus in the genome in which
variation between individuals is associated with a quantitative
gene expression trait, often measured as messenger RNA abun-
dance. The RegulomeDB database identifies whether the SNPs
are located within known or predicted regulatory elements in the
intergenic regions of the human genome. We focused particularly
on data obtained from experiments using tissues relevant to cer-
ebrovascular phenotypes, specifically CNS (brain and spinal cord)
and vasculature.
We also explored whether SNPs with significant associations
were in LD with the rare SNPs previously reported from sequenc-
ing studies to be associated with sporadic ICH.9,10 We used the
Web-based tool SNAP.26 If the SNP was not included in SNAP,
we used the Haploview program to check whether the SNP
(based on its position) was in the same haplotype block as the
previously reported rare SNPs.32
RESULTS Significance threshold. Based on the geno-
type data from the HapMap II CEU dataset, the
effective number (N) of SNPs tested was 598, giving
a final Nyholt significance threshold of p 5
0.000084. This compares to the Bonferroni-
corrected p value of 0.00005 and a genome-wide
significance p value of 5 3 1028.
Meta-analyses of COL4A1/COL4A2 SNPs for each
phenotype. Based on our significance threshold of
p 5 0.000084, 3 common SNPs in COL4A2 were
significantly associated with the deep ICH phenotype
(rs9521732: OR per additional A allele5 1.28, 95%
CI 1.13–1.44, p 5 0.00007; rs9521733: OR per
additional C allele 5 1.29, 95% CI 1.14–1.46,
p 5 0.00003; rs9515199: OR per additional C
allele 5 1.28, 95% CI 1.14–1.44, p 5 0.00006)
(figure 1, table 2). These 3 SNPs are all intronic
and in high LD with each other (table 2). One
(rs9521733) was directly genotyped in the majority
of the cohorts while 2 were imputed in all (rs951599)
or in the majority (rs9521732) of the cohorts (table
e-2). There were no statistically significant associa-
tions of common SNPs in COL4A1/COL4A2 with
any of the other phenotypes.
Associations with other cerebrovascular phenotypes of
the 3 COL4A2 SNPs significantly associated with deep
ICH. Figure 2 shows association results for the 3 SNPs
significantly associated with deep ICH across all 9
phenotypes assessed. Although these 3 SNPs were
significantly associated only with deep ICH, there were
suggestive associations with 2 other cerebral SVD phe-
notypes: lacunar ischemic stroke (rs9521732: OR
1.09, 95% CI 1.02–1.17, p 5 0.01639; rs9521733:
OR 1.10, 95% CI 1.03–1.18, p 5 0.00734;
rs9515199: OR 1.09, 95% CI 1.02–1.17, p 5
0.0145) and WMH volume in symptomatic ischemic
stroke cases (rs9521732: OR 1.07, 95% CI 1.01–
1.14, p 5 0.01442; rs9521733: OR 1.07, 95% CI
1.01–1.13, p 5 0.01642; rs9515199: OR 1.07,
95% CI 1.01–1.14, per 1 SD change in WMH vol-
ume; p 5 0.0145). There was no evidence for associa-
tion of these SNPs with other non-SVD stroke subtypes
(lobar ICH, CE, and LVD ischemic stroke) or for
WMH volume in population-based studies (figure 2).
As expected, ORs for these SNPs with the all ICH and
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all ischemic stroke phenotypes were intermediate
between those for deep and lobar ICH and for
lacunar and non-SVD ischemic stroke subtypes,
respectively, suggesting that associations with these
combined phenotypes were driven by results for deep
ICH and lacunar ischemic stroke (figure 2).
The associations across individual cohorts included
in the deep ICH meta-analysis were highly consistent,
with no significant heterogeneity (I2 5 0%; p . 0.9)
(figure 3). There was no or minimal heterogeneity
between the individual cohorts’ results for lacunar
ischemic stroke (I2 5 0%; p . 0.8) and for WMH
in ischemic stroke (I2 5 17%–22%; p . 0.2).
Functional annotation of SNPs. We identified 92
unique SNPs in moderate LD (r2 $ 0.3) with the 3
significant SNPs from our analyses. All of these SNPs
(including our 3 significant SNPs) are intronic (table
e-3). From these, we then selected all 5 SNPs that
were in high LD (r2 . 0.9) with our 3 significant
SNPs, giving a total of 8 SNPs for analysis of func-
tional annotation. The GTEx eQTL browser search
revealed no significant eQTLs for any of these 8
SNPs. However, the RegulomeDB database search
revealed minimal binding evidence for 4 of the 8
SNPs, suggesting that these SNPs are located in areas
of the genome that may have some regulatory func-
tions. When we considered only results based on ex-
periments done on tissues most relevant to
cerebrovascular phenotypes (brain, spinal cord, and
blood vessels), there was still some evidence for these
4 SNPs being located in genomic areas of potential
functional significance (table e-3).
Table 2 SNPs significantly associated with the deep ICH phenotype
SNP Gene Allelesa Functional annotation p Value MAF r2
rs9521732 COL4A2 A/C Intronic 0.0000652 A 5 0.413 rs9521733 5 0.896; rs9515199 5 1
rs9521733 COL4A2 C/T Intronic 0.0000339 C 5 0.404 rs9515199 5 0.896; rs9521732 5 0.896
rs9515199 COL4A2 C/T Intronic 0.0000599 C 5 0.414 rs9521733 5 0.896; rs9521732 5 1
Abbreviations: ICH 5 intracerebral hemorrhage; MAF 5 minor allele frequency; SNP 5 single nucleotide polymorphism.
a Risk allele is marked in bold.
r2 5 measure of linkage disequilibrium; intronic 5 located in a noncoding region of the gene.
Figure 1 Regional association plot for deep ICH meta-analysis
Dots mark individual SNPs; y-axis: p value for association between each SNP and deep ICH; x-axis: position of SNPs. Most
significantly associated SNP shown in purple; colors for other SNPs depend on linkage disequilibrium with this lead SNP (see
r2 color coding on figure). Recombination: exchange of a segment of DNA between 2 homologous chromosomes during
meiosis leading to a novel combination of genetic material in the offspring. Recombination rate: measured as frequency of
exchange per unit physical distance (centimorgan [cM]/mega base pair [Mb]). cM: unit of linkage that refers to the distance
between 2 gene loci determined by the frequency with which recombination occurs between them. Two loci are said to be
1 cM apart if recombination is observed between them in 1% of meioses. Mb: a unit of length of nucleic acids, equal to
1 million base pairs. ICH 5 intracerebral hemorrhage; SNP 5 single nucleotide polymorphism.
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The 3 rare exonic COL4A2 SNPs reported in a pre-
vious sequencing study to be associated with sporadic
ICH are rs117412802, rs62621875, and A1690T
(hg19 position: 111164467).9 Based on SNAP,
rs117412802 was not in LD with the 3 SNPs signifi-
cantly associated with deep ICH in our analyses (r25 0).
rs62621875 and A1690T were not represented in
SNAP, but in Haploview, they were not in the same
haplotype block as the 3 SNPs significantly associated
with deep ICH in our analyses, suggesting that they
are not in close LD with the SNPs we identified.
DISCUSSION Herein, we present the first evidence
for a significant association between an intronic locus
in COL4A2 and deep ICH, a symptomatic cerebral
SVD phenotype. We also found suggestive associa-
tions in the same direction for these SNPs with other
cerebral SVD phenotypes: lacunar ischemic stroke
Figure 2 Associations between the 3 SNPs significantly associated with deep ICH across all phenotypes
Figure represents pooled odds ratios across all cohorts. Significant or suggested associations in cerebral small vessel dis-
ease phenotypes are shown in red. Data for rs9521733 were unavailable in the WMH in population cohorts. CE 5 cardi-
oembolic; CI 5 confidence interval; ICH 5 intracerebral hemorrhage; IS 5 ischemic stroke; LVD 5 large vessel disease;
SNP 5 single nucleotide polymorphism; WMH 5 white matter hyperintensity.
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and WMH in ischemic stroke cases. Our results indi-
cate that the COL4A2 gene is a locus conferring risk
for common forms of symptomatic cerebral SVD,
particularly deep ICH.
We did not find evidence for an association
between these 3 SNPs (or any others in the
COL4A1/COL4A2 region) and WMH assessed in
largely asymptomatic individuals in population-
based studies. The difference in results between
WMH assessed among symptomatic people with
ischemic stroke and among those in population-
based studies (both of which are often regarded as
cerebral SVD phenotypes) could be attributable to
genuine differences in the nature of the phenotype
represented by WMH in these different groups and
its genetic influences, differences in scanning and
measurement techniques used in the contributing co-
horts, or the play of chance.
Our findings are supported by other data showing
the importance of the COL4A1/COL4A2 genes in
cerebrovascular disease. Missense mutations in
COL4A1 or COL4A2 lead to rare mendelian forms
of cerebrovascular disease including pediatric and
adult cerebral hemorrhage.6,7 Furthermore, sequence
analysis of COL4A1 and COL4A2 has revealed
missense mutations in sporadic cases of ICH (96 cases
and 145 controls), supporting an important role for
collagen IV in the etiology of cerebral hemorrhage.9,10
Studies in mice and patients have shown that the
severe dominant mutations lead to basement
membrane defects, which may weaken the blood ves-
sel and also affect vascular function. In addition to the
basement membrane defects, the missense mutations
lead to retention of mutant protein in the endoplas-
mic reticulum, leading to endoplasmic reticulum
stress and activation of the unfolded protein
response.9,33–35 It is of interest that the SNPs identi-
fied in our study, and all SNPs in moderate LD with
them, are intronic, and may be located in regulatory
areas of the gene. The 3 SNPs from our analysis are
not in close LD with the variants reported from pre-
vious sequence analyses in sporadic ICH, demonstrat-
ing that they do not represent the same signal as that
observed from the previously described exonic rare
variants, but instead identify a novel intronic region
of COL4A2 associated with deep ICH (and, possibly,
with other cerebral SVD phenotypes).
Our study has several strengths. We investigated a
specific, prespecified hypothesis, clearly defining the
clinical phenotypes and candidate genes of interest,
based on preexisting supporting data. We used a
novel approach, investigating genetic associations
across a range of cerebrovascular phenotypes, focusing
on a specific cerebrovascular subphenotype—cerebral
SVD—which is thought to have distinct pathophys-
iologic mechanisms and risk factors. A further
strength is that, through a network of collaborative
groups largely under the umbrella of the International
Stroke Genetics Consortium, we were able to include
in our in silico analyses the majority of the currently
available data representing the phenotypes included
for the COL4A1/2 region from genotyped cohorts
among white individuals of European ancestry.
Our study has some limitations. While we have
shown that SNPs in COL4A2 are associated with
deep ICH, when we analyze data for the specific can-
didate COL4A1/2 region, correcting appropriately for
multiple testing within that region by using the gen-
erally accepted Nyholt method,2,21–24 this association
did not reach a genome-wide level of significance
(possible reasons include study size),4 while associa-
tions with other cerebral SVD phenotypes (lacunar
ischemic stroke and WMH in ischemic stroke cases)
were suggestive but not independently robust to mul-
tiple testing. In addition, although we corrected
appropriately for the number of SNPs in the region,
we did not adjust the statistical threshold for the
number of phenotypes investigated. We considered
that this would be overly conservative since these
phenotypes are not completely independent of each
other. As in any meta-analysis, this study is dependent
on accurate allocation of cases and controls, and accu-
rate phenotype measurements in the original studies.
Figure 3 Associations of significant single nucleotide polymorphisms across
cohorts included in the meta-analysis of deep intracerebral
hemorrhage
Heterogeneity: rs9521732: x22df 5 0.09, p 5 0.9563, I2 5 0%; rs9521733: x22df 5 0.02,
p 5 0.9903, I2 5 0%; rs9515199: x22df 5 0.08, p 5 0.9607, I2 5 0%. CI 5 confidence
interval; GERFHS 5 Genetic and Environmental Risk Factors for Hemorrhagic Stroke; GO-
CHA 5 Genetics of Cerebral Hemorrhage with Anticoagulation; ISGC 5 International Stroke
Genetics Consortium.
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Thus, there is a risk that premorbid controls may have
been misallocated, although this was addressed in the
original studies by matching the controls to cases
based on age.
Our findings certainly merit further confirmatory
studies in additional, large samples with relevant phe-
notypes, including those from individuals of non-
European ancestry. It would also be of interest to
extend genetic association studies of this genomic
region to other cerebral SVD phenotypes that are
likely to have a similar underlying vascular pathology,
such as MRI-detected brain microbleeds (particularly
deep brain microbleeds) and clinically silent lacunar
infarcts. Relevant data to facilitate such further anal-
yses are likely to become available from the ISGC
ICH GWAS, CHARGE, the US National Institute
of Neurological Disorders and Stroke–funded SiGN
(Stroke Genetics Network) ischemic stroke GWAS,
and other consortia in the near future.3,4,36 Further
deep sequencing of the entire COL4A1/2 genomic
region (intronic as well as exonic regions, given pre-
vious exonic and the current intronic findings) among
cases of ICH as well as other cerebral SVD pheno-
types, with functional studies of promising variants
thus identified, are also needed to further investigate
potential pathogenic mechanisms underlying spo-
radic forms of cerebral SVD. Finally, this successful
approach of identifying promising candidates for the
cerebral SVD phenotype based on rare familial forms
of the disease could be extended to include other rel-
evant candidate genes.
Our study lays important foundations for enhanc-
ing knowledge of the genetic risk factors underlying
cerebral SVD, a disease of major public health impor-
tance. The approach taken should lead to further
understanding of causative pathways and identifica-
tion of a subset of patients with cerebrovascular dis-
ease unified by their disease mechanism who may
benefit from distinct prevention and treatment
strategies.
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